SOUTH SAN FRANCISCO, Calif., Feb 24, 2011 (BUSINESS WIRE) -- Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael Morrissey, Ph.D., the company's president and chief executive officer, will present at the upcoming Citi 2011 Global Health Care Conference at 3:30 p.m. EST / 12:30 p.m. PST on Tuesday, March 1, 2011 in New York. Dr. Morrissey will review the latest clinical data for cabozantinib (XL184) in castration-resistant prostate cancer (CRPC), which were presented at the ASCO Genitourinary Cancers Symposium earlier this month, and will discuss the pivotal trial plans and regulatory strategy for the compound in CRPC. He will also discuss the company's 2011 financial outlook and provide a general business update.

The event will be webcast and may be accessed in the Event Calendar page under Investors at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at www.exelixis.com.

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President
Investor Relations and Corporate Communications
cbutler@exelixis.com